Life Sciences

Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases
20 July 2022

Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet...

Read more
String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).
11 July 2022

String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).

String Bio (String) and Woodside Energy are collaborating on potential production of sustainable protein ingredients from greenhouse gases.
Woodside Energy has invested...

Read the press release
Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™
23 June 2022

Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™

Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy...

Read more
Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC
23 June 2022

Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC

GB1211, Galecto's galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models

Read the press release
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
6 June 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read more
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
6 June 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read more
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
2 June 2022

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read the press release
Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin
24 May 2022

Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin

DERMALA, the only personalized, clinically proven treatment for acne powered by the human microbiome, extends its product range to include a second microbiome-powered line of...

Read more
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
24 May 2022

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details...

Read more
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
3 May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec...

Read more

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse